The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form
Open accessAbstract
Objective To establish a score threshold that constitutes a clinically relevant change for each domain of the Expanded Prostate Cancer Index Composite - Short Form (EPIC-26). While its use in clinical practice and clinical trials has increased worldwide, the clinical interpretation of this 26-item disease-specific patient-reported quality of life questionnaire for men with localized prostate cancer would be facilitated by characterization of score thresholds for clinically relevant change (the minimally important differences, or MID). Methods We used distribution- and anchor-based approaches to establish the MID range for each EPIC-26 domain (urinary, sexual, bowel, hormonal) based on a prospective, multi-institutional cohort of 1,201 men treated for prostate cancer between 2003 and 2006 and followed for 3 years after treatment. For the anchor-based approach, we compared within/between subject score changes for each domain to an external “anchor” measure of overall cancer treatment satisfaction. Results We found the bowel and vitality/hormonal domains to have the lowest MID range (a 4–6 point change should be considered clinically relevant), while the sexual domain had the greatest MID values (10–12). Urinary incontinence appeared to have a greater MID range (6–9) compared with the urinary irritation/obstruction domain (5–7). Conclusions Using two independent approaches, we established the minimally important differences for each EPIC-26 domain. Definition of these MID values is essential for the researcher or clinician to understand when changes in symptom burden among prostate cancer survivors are clinically relevant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074311 · Cited by 2,253
Self-citationThe Use of Psychological Testing for Treatment Planning and Outcome Assessment
Maruish, M. E., & Leahy, R. L. (2000) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.14.2.205 · Cited by 1,634
Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M., & Sanda, M. G. (2000) · Urology · doi:10.1016/s0090-4295(00)00858-x · Cited by 1,520
Self-citationA point of minimal important difference (MID): a critique of terminology and methods
King, M. T. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.9 · Cited by 646
Beal, A. C. (2012) · JAMA · doi:10.1001/jama.2012.500 · Cited by 623
Responsiveness and minimal important differences for patient reported outcomes
Revicki, D. A., Cella, D., Hays, R. D., Sloan, J. A., Lenderking, W. R., & Aaronson, N. K. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-70 · Cited by 476
Estimating clinically significant differences in quality of life outcomes
Wyrwich, K. W., Bullinger, M., Aaronson, N., Hays, R. D., Patrick, D. L., & Symonds, T. (2005) · Quality of Life Research · doi:10.1007/s11136-004-0705-2 · Cited by 471
Szymanski, K. M., Wei, J. T., Dunn, R. L., & Sanda, M. G. (2010) · Urology · doi:10.1016/j.urology.2010.01.027 · Cited by 456
Self-citationEton, D. T., Cella, D., Yost, K. J., Yount, S. E., Peterman, A. H., Neuberg, D. S., Sledge, G. W., & Wood, W. C. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.01.012 · Cited by 390
Cited by
Hamstra, D. A., Mariados, N., Sylvester, J., Shah, D., Karsh, L., Hudes, R., Beyer, D., Kurtzman, S., Bogart, J., Hsi, R. A., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.12.024 · Cited by 384
Self-citationBarocas, D. A., Alvarez, J., Resnick, M. J., Koyama, T., Hoffman, K. E., Tyson, M. D., Conwill, R., McCollum, D., Cooperberg, M. R., Goodman, M., et al. (2017) · JAMA · doi:10.1001/jama.2017.1704 · Cited by 344
Kishan, A. U., Ma, T. M., Lamb, J. M., Casado, M., Wilhalme, H., Low, D. A., Sheng, K., Sharma, S., Nickols, N. G., Pham, J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6558 · Cited by 323
Tree, A. C., Ostler, P., van der Voet, H., Chu, W., Loblaw, A., Ford, D., Tolan, S., Jain, S., Martin, A., Staffurth, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00517-4 · Cited by 313
Hoffman, K. E., Penson, D. F., Zhao, Z., Huang, L.-C., Conwill, R., Laviana, A. A., Joyce, D. D., Luckenbaugh, A. N., Goodman, M., Hamilton, A. S., et al. (2020) · JAMA · doi:10.1001/jama.2019.20675 · Cited by 298
Metadata
- Authors
- Skolarus, T. A., Dunn, R. L., Sanda, M. G., Chang, P., Greenfield, T. K., Litwin, M. S., Wei, J. T., Regan, M., Hembroff, L., Wei, J. T., Hamstra, D., Dunn, R., Northouse, L., Wood, D., Klein, E. A., Ciezki, J., Michalski, J., Andriole, G., Litwin, M., Saigal, C., Greenfield, T., Pisters, L., Kuban, D., Sandler, H., Hu, J., Kibel, A., Dahl, D., Zietman, A., Chang, P., Wagner, A., Kaplan, I., & Sanda, M. G.
- Venue
- Urology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 85
- Issue
- 1
- Pages
- 101-106
- ISSN
- 0090-4295 (ISSN-L)
- OpenAlex
- W2017622807
- Cited by
- 335
- References
- 27
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. https://app.cochat.ai/papers/10.1016/j.urology.2014.08.044
- The paper
- Skolarus, T. A., Dunn, R. L., Sanda, M. G., Chang, P., Greenfield, T. K., Litwin, M. S., Wei, J. T., Regan, M., Hembroff, L., Wei, J. T., Hamstra, D., Dunn, R., Northouse, L., Wood, D., Klein, E. A., Ciezki, J., Michalski, J., Andriole, G., Litwin, M., . . . Sanda, M. G. (2015). Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. https://doi.org/10.1016/j.urology.2014.08.044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.